Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Treatment for Ulcerative Colitis: Supporting Mucosal Healing and Reducing Flares
Transcript
- 0:00SPEAKER_01: Welcome to this AuronaCell Podcast.
- 0:02SPEAKER_01: If you are dealing with ulcerative colitis, your body is essentially, well, fighting a brutal, highly localized war against itself.
- 0:11SPEAKER_00: Yeah, it really is.
- 0:12SPEAKER_01: Right.
- 0:12SPEAKER_01: But what if the ultimate solution isn't to violently suppress your immune system, but to completely reboot its communication network?
- 0:21SPEAKER_01: So welcome to today's deep dive.
- 0:23SPEAKER_01: We are taking a fascinating look at the science behind stem cell treatment for ulcerative colitis.
- 0:28SPEAKER_00: Specifically how it supports, you know, mucosal healing and drastically reduces disease flares.
- 0:34SPEAKER_01: Exactly.
- 0:34SPEAKER_01: It's such a critical conversation to have, primarily because for anyone living with UC, that relentless cycle of flares and temporary remissions is just absolutely exhausting.
- 0:43SPEAKER_00: Aaron Powell Totally exhausting.
- 0:44SPEAKER_00: And to guide us today, we are diving into clinical documents and detailed materials straight from Cyrenicell.
- 0:50SPEAKER_00: Right.
- 0:50SPEAKER_00: Yeah.
- 0:50SPEAKER_00: They are a doctor-led stem cell therapy and regenerative medicine center.
- 0:54SPEAKER_00: They're based out of Kuala Lumpur and Cybergya, Malaysia.
- 0:58SPEAKER_01: Aaron Powell But they also have this massive international footprint, right?
- 1:01SPEAKER_01: Looking at their patient demographics in the sources, they are treating people flying in from Australia, the Middle East, all over the world.
- 1:08SPEAKER_00: Yeah, people who are specifically seeking out this structured medically supervised cell therapy.
- 1:14SPEAKER_01: And, you know, going through their clinical literature gave me this massive aha moment.
- 1:19SPEAKER_01: I realized my entire mental model for stem cells was just wrong.
- 1:24SPEAKER_00: How so?
- 1:25SPEAKER_01: Well, I thought they were like biological spare parts, but they aren't.
- 1:29SPEAKER_01: They act as the communication reset button for an immune system that has essentially lost its mind.
- 1:34SPEAKER_00: Aaron Powell That framework changes everything about how we understand regenerative medicine.
- 1:38SPEAKER_00: It really does.
- 1:39SPEAKER_01: It totally slips it.
- 1:40SPEAKER_00: Yeah.
- 1:40SPEAKER_00: But before we can appreciate how a clinic like Serona Cell utilizes this technology, we really need to understand the frustrating brick wall that standard UC treatments inevitably hit.
- 1:51SPEAKER_00: We have to look at the unique nature of the battlefield itself.
- 1:54SPEAKER_01: Aaron Powell Let's establish that baseline then.
- 1:56SPEAKER_01: What does the specific battlefield of ulcerative colitis look like compared to, say, other gut issues?
- 2:02SPEAKER_00: Aaron Powell Well, the contrast with Crohn's disease is probably the best way to understand it.
- 2:06SPEAKER_01: Okay.
- 2:06SPEAKER_00: So Crohn's can erupt anywhere from the mouth down to the gastrointestinal tract, and the inflammation penetrates through the entire thickness of the gut wall.
- 2:15SPEAKER_00: It's very erratic, you know, very patchy.
- 2:18SPEAKER_01: Right.
- 2:18SPEAKER_01: It can pop up anywhere.
- 2:19SPEAKER_00: Trevor Burrus, Jr.
- 2:19SPEAKER_00: Exactly.
- 2:20SPEAKER_00: But ulcerative colitis is entirely different.
- 2:24SPEAKER_00: It is strictly confined to the continuous inner lining of the colon and the rectum.
- 2:28SPEAKER_01: Aaron Powell So it's a uh a highly localized superficial battleground, essentially.
- 2:33SPEAKER_00: Aaron Ross Powell Yes, exactly.
- 2:34SPEAKER_00: It is contained to one continuous mucosal layer.
- 2:37SPEAKER_00: And that localized nature is actually a major reason why mesenchymal stem cell therapy, MSC therapy demonstrates such consistent targeted results in these UC clinical trials.
- 2:48SPEAKER_01: Aaron Ross Powell Because the immune cells driving the destruction are concentrated in one specific geographic area.
- 2:54SPEAKER_00: You hit the nail on the head.
- 2:55SPEAKER_01: But you know, knowing where the battle is happening doesn't make it any less brutal for the person actually enduring it.
- 3:00SPEAKER_00: Not at all.
- 3:01SPEAKER_01: The materials we are looking at describe just a harrowing reality for you if you're dealing with this.
- 3:07SPEAKER_01: A patient enters a flare, which means severe abdominal cramps, an urgent, uncontrollable need to go, loose stools filled with blood and mucus.
- 3:18SPEAKER_00: And that crushing systemic fatigue.
- 3:20SPEAKER_01: Oh, yeah, the kind of fatigue that makes simply getting out of bed feel impossible.
- 3:24SPEAKER_01: It derails careers, it destroys social lives, and wreaks absolute havoc on mental health.
- 3:29SPEAKER_00: It's devastating.
- 3:30SPEAKER_01: And then maybe the disease quiets down into remission for a few months.
- 3:34SPEAKER_00: Right.
- 3:34SPEAKER_00: Only for the cycle to begin all over again.
- 3:36SPEAKER_00: And that vicious loop brings us directly to the well, the blind spot of standard medical care.
- 3:41SPEAKER_01: Aaron Powell, which is what exactly?
- 3:42SPEAKER_00: Aaron Powell Well, the conventional arsenal usually involves amino salicillates, corticosteroids, heavy immunosuppressants and biologics.
- 3:49SPEAKER_01: That heavy itters.
- 3:50SPEAKER_00: Yeah.
- 3:51SPEAKER_00: But these drugs are fundamentally designed to just mute, suppress, or redirect specific parts of your immune response just to put out the fire of inflammation.
- 3:59SPEAKER_01: Aaron Powell I was actually thinking about this whole standard approach.
- 4:02SPEAKER_01: And it feels a bit like baling water out of a sinking boat without ever bothering to patch the hole in the hole.
- 4:08SPEAKER_00: That's a really good analogy.
- 4:10SPEAKER_01: Right.
- 4:10SPEAKER_01: Because you are working incredibly hard taking these massive medications just to keep the boat afloat, but the water just keeps rushing in.
- 4:18SPEAKER_01: So why do these heavy-duty, state-of-the-art biologic drugs eventually just stop working for so many people?
- 4:25SPEAKER_00: Because the immune system is fundamentally designed to find workarounds.
- 4:28SPEAKER_01: It's too smart.
- 4:29SPEAKER_00: Exactly.
- 4:30SPEAKER_00: Biologics are essentially sniper rifles.
- 4:33SPEAKER_00: They target one specific inflammatory pathway or, you know, one specific protein.
- 4:38SPEAKER_00: Okay.
- 4:38SPEAKER_00: So when you block that single pathway, the body assumes it is being thwarted by a dangerous infection.
- 4:44SPEAKER_01: Oh wow.
- 4:45SPEAKER_00: Right.
- 4:45SPEAKER_00: It reacts by simply opening a completely different inflammatory pathway.
- 4:50SPEAKER_00: You bail the water, but the immune system just drills a new hole in the boat.
- 4:54SPEAKER_00: You haven't actually fixed the underlying cellular confusion.
- 4:57SPEAKER_00: Trevor Burrus, Jr.
- 4:58SPEAKER_01: And doing this indefinitely comes with a staggering cost, right?
- 5:01SPEAKER_00: A massive long-term toll on the body.
- 5:04SPEAKER_00: Continuously suppressing the immune system leaves a patient highly vulnerable.
- 5:08SPEAKER_01: Aaron Powell To what kind of things?
- 5:09SPEAKER_00: Well, we are looking at a significantly heightened risk of serious opportunistic infections, the reactivation of dormant diseases like tuberculosis and severe bone density loss.
- 5:20SPEAKER_01: Like osteocorosis.
- 5:21SPEAKER_00: Yes, osteoporosis, which is a very common fallout from long-term steroid use.
- 5:26SPEAKER_00: Patients are trapped in an impossible choice.
- 5:28SPEAKER_01: Aaron Powell Endure the agonizing pain of a flare or accept the long-term systemic dangers of heavy immune suppression.
- 5:36SPEAKER_00: Exactly.
- 5:37SPEAKER_00: It's a terrible position to be in.
- 5:38SPEAKER_01: Which means if standard drugs are doing exactly what they're designed to do, suppressing the immune response, but the gut keeps flaring up anyway, we need a totally different mechanism.
- 5:47SPEAKER_00: Aaron Powell We need something that actively changes the immune environment rather than just muting it.
- 5:51SPEAKER_01: And that brings us to the science of mesenchymal stem cells.
- 5:55SPEAKER_01: But uh before we get into the mechanics of how MSEs fix the hole in the boat, let's address where these cells actually come from.
- 6:00SPEAKER_01: Because the Cyrona cell materials are super adamant about their ethical standards.
- 6:05SPEAKER_00: Yeah, and sourcing is the absolute bedrock of safe regenerative medicine.
- 6:09SPEAKER_00: The documents outline that Cyrona cell exclusively uses ethically sourced early passage WJMSCs.
- 6:16SPEAKER_01: Okay, what does the WJ stand for?
- 6:18SPEAKER_00: The WJ refers to Wharton's jelly.
- 6:20SPEAKER_00: Got it.
- 6:20SPEAKER_00: This is the highly specialized tissue found inside donated umbilical cords from healthy full-term deliveries, and it's obtained with absolute explicit donor consent.
- 6:30SPEAKER_01: And the processing environment is just as crucial.
- 6:33SPEAKER_01: The sources mentioned they are produced under CGMP and BSL2 laboratory standards.
- 6:38SPEAKER_00: Which is vital.
- 6:39SPEAKER_01: Yeah.
- 6:39SPEAKER_01: And for anyone wondering, those aren't just fancy acronyms to put on a brochure.
- 6:43SPEAKER_01: ESL2 and CGMP mean these cells are processed in tightly regulated, sterile, pharmaceutical grade laboratories.
- 6:50SPEAKER_00: They run rigorous checks for identity, sterility, and viability.
- 6:53SPEAKER_01: Right.
- 6:54SPEAKER_01: So you are getting a pure standardized dose, completely free of contamination.
- 6:57SPEAKER_01: And honestly, the biggest takeaway here is what they don't use.
- 7:00SPEAKER_00: Yes, they absolutely never use embryonic stem cells or experimental, unpredictable, pluripotent stem cells.
- 7:06SPEAKER_01: They're entirely utilizing adult-derived cells.
- 7:09SPEAKER_00: Exactly.
- 7:10SPEAKER_00: This provides a deeply consistent supply of young, robust cells possessing incredibly potent anti-inflammatory properties without the ethical controversies or the unpredictability of embryonic cells.
- 7:24SPEAKER_01: Okay.
- 7:24SPEAKER_01: I need to stop you there because this is where my own brain got completely stuck when I was reading this.
- 7:29SPEAKER_00: What part?
- 7:29SPEAKER_01: I always assumed, and I think a lot of people do, that a stem cell infusion meant these young, healthy cells travel down to your damaged colon, plant themselves into the tissue like seeds in a garden, and literally transform into brand new colon cells.
- 7:45SPEAKER_00: Well, yeah.
- 7:46SPEAKER_00: It is the most persistent misconception in regenerative medicine.
- 7:49SPEAKER_00: Right.
- 7:50SPEAKER_00: Yeah.
- 7:50SPEAKER_00: But the reality of how they function is far more sophisticated.
- 7:54SPEAKER_00: The primary action of MSCs is not to take root permanently.
- 7:57SPEAKER_00: They operate through something called a peracrine mechanism.
- 8:02SPEAKER_01: If they aren't planting themselves permanently, aren't we just talking about a really expensive temporary drug that gets flushed out of the body in a few days?
- 8:08SPEAKER_00: It's a fair question.
- 8:09SPEAKER_01: How does a temporary visitor create a permanent fix?
- 8:12SPEAKER_00: Think of it as a biological hit and run, but in the best way possible.
- 8:16SPEAKER_01: Okay.
- 8:16SPEAKER_01: Like that.
- 8:17SPEAKER_00: When MSCs are introduced into the body, typically through a standard IV infusion, they circulate through the bloodstream like an elite internal reconnaissance team.
- 8:27SPEAKER_00: They are utilizing a process called chemotaxis.
- 8:30SPEAKER_00: Essentially, inflamed damaged tissue in the gastrointestinal tract sends out chemical SOS signals.
- 8:38SPEAKER_01: Like a flare gun.
- 8:39SPEAKER_00: Exactly.
- 8:40SPEAKER_00: And the MSCs act like blood hounds.
- 8:43SPEAKER_00: They pick up the scent of those specific inflammatory proteins in the blood and migrate directly to the source of the fire.
- 8:49SPEAKER_00: Trevor Burrus, Jr.
- 8:49SPEAKER_01: So they track the distress signal right to the colon.
- 8:52SPEAKER_00: Yes.
- 8:52SPEAKER_00: But once they arrive at the site of the damage, they don't turn into bricks to rebuild the wall themselves.
- 8:57SPEAKER_00: Instead, they act as master project managers.
- 9:00SPEAKER_01: Aaron Powell Okay, what do the project managers do?
- 9:02SPEAKER_00: They release a highly complex payload of specific molecules that fundamentally alter the behavior of all the surrounding native cells.
- 9:12SPEAKER_00: That is the pericrine effect in action.
- 9:14SPEAKER_00: In a patient with UC, the immune system is entirely broken.
- 9:18SPEAKER_00: Pro-inflammatory cells are dominating the area, violently attacking the colon tissue, even though there is no bacterial or viral infection to fight.
- 9:25SPEAKER_01: Friendly fire.
- 9:26SPEAKER_00: Severe friendly fire.
- 9:27SPEAKER_00: When the MSCs arrive, they force a massive systemic immune reset across the entire battlefield simultaneously.
- 9:44SPEAKER_00: Which is huge.
- 9:46SPEAKER_01: Imagine TNF Alpha, Interleukin 6, and Interleukin 17 as the biochemical fire alarms.
- 9:51SPEAKER_00: Yes.
- 9:52SPEAKER_01: They are the chemical messengers screaming, attack, destroy at your own tissue.
- 9:56SPEAKER_01: The MSCs walk into the room and immediately cut the wires to those alarms.
- 10:00SPEAKER_01: The aggressive signals just plummet.
- 10:01SPEAKER_00: And while they are cutting the wires to the attack alarms, the MSCs are simultaneously amplifying a completely different set of signals, TGF beta IL10, and PGE2.
- 10:10SPEAKER_01: Peacemakers.
- 10:11SPEAKER_00: Exactly the peacemakers.
- 10:13SPEAKER_00: These specific molecules force the patient's immune system to massively expand its production of regulatory T cells.
- 10:20SPEAKER_01: The emergency breaks.
- 10:21SPEAKER_00: The heavy-duty emergency breaks of the human immune system.
- 10:24SPEAKER_00: The expanded army of regulatory T cells circulates through the tissue, forcefully telling the aggressive immune cells to stand down and restore order.
- 10:34SPEAKER_00: Wow.
- 10:34SPEAKER_00: They physically stop the immune system from attacking the healthy colon tissue.
- 10:39SPEAKER_00: And notice how this fundamentally differs from a biologic drug.
- 10:42SPEAKER_01: Aaron Ross Powell Right, because a biologic acts as a roadblock for one single alarm wire.
- 10:47SPEAKER_00: Trevor Burrus Exactly.
- 10:47SPEAKER_00: MSCs regulate the entire battlefield, turning off the alarms while simultaneously slamming on the brakes.
- 10:53SPEAKER_01: So the active war finally stops, the immune system is calmed down, the constant friendly fire attacks cease, and the body finally gets a moment of breathing room.
- 11:02SPEAKER_00: And that space allows it to do something those standard immunosuppressant medications simply cannot do.
- 11:07SPEAKER_01: Which is physically rebuild the damaged structural lining of the gut.
- 11:10SPEAKER_00: Yes.
- 11:11SPEAKER_00: Gastroenterologists refer to this physical rebuilding as mucosal healing.
- 11:16SPEAKER_00: In the modern management of ulcerative colitis, mucosal healing has really become the absolute gold standard of care.
- 11:23SPEAKER_01: Because just feeling better on a Tuesday, you know, getting temporary symptom relief isn't enough to secure your long-term health.
- 11:32SPEAKER_00: Far from it.
- 11:33SPEAKER_00: If your daily symptoms vanish, but the microscopic lining of your colon remains damaged, ulcerated, and fragile, you are incredibly vulnerable.
- 11:41SPEAKER_01: The slightest trigger will launch you right back into a severe flair.
- 11:44SPEAKER_00: Precisely.
- 11:45SPEAKER_00: However, if a patient achieves true mucosal healing where the tissue physically repairs itself, the long-term statistics change drastically.
- 11:52SPEAKER_01: We see significantly lower relapse rates.
- 11:54SPEAKER_00: Far less time spent hospitalized, a decreased reliance on heavy long-term medications, and crucially a markedly lower risk of developing colon cancer.
- 12:03SPEAKER_01: Which is a very real looming danger for patients who endure years of active simmering gut inflammation.
- 12:08SPEAKER_00: It really is.
- 12:09SPEAKER_01: Okay, so if the MSCs are the project managers and they've stopped the active fighting, how do they actually instruct the local native cells to start the physical rebuilding process?
- 12:20SPEAKER_00: They deploy the construction crew.
- 12:22SPEAKER_00: Through that same paracron action we discussed, MSCs release an array of very specific growth factors that stimulate the surviving cells lining the colon and rectum.
- 12:31SPEAKER_01: Let's look at the specific growth factors the documents highlight, because they each have a distinct job.
- 12:36SPEAKER_01: We have HGF and EGF.
- 12:38SPEAKER_00: Right.
- 12:45SPEAKER_00: Okay.
- 12:45SPEAKER_00: They directly drive the accelerated turnover of healthy gut lining cells, pushing them to quickly multiply and stretch across the ulcerated, damaged areas.
- 12:54SPEAKER_01: And then there's a fascinating one.
- 12:59SPEAKER_00: VEGF is vital for survival.
- 13:01SPEAKER_00: In a state of active UC, the intestinal tissue is heavily scarred and poorly supplied with blood.
- 13:07SPEAKER_00: The tissue is literally starving.
- 13:09SPEAKER_01: So what does VEGF do?
- 13:10SPEAKER_00: It stimulates the formation of brand new blood vessels.
- 13:14SPEAKER_00: It builds fresh supply lines, bringing vital oxygen and nutrients directly into that starving tissue so the cellular builders actually have the energy to do their work.
- 13:23SPEAKER_01: Let's try to visualize this structural repair.
- 13:25SPEAKER_01: Right.
- 13:26SPEAKER_01: Because it's the core of how flares are actually stopped.
- 13:30SPEAKER_01: If we think of a healthy gut lining, like a formidable medieval castle wall.
- 13:35SPEAKER_00: Where the heavy stones are locked tightly together, leaving no gaps.
- 13:38SPEAKER_01: Right.
- 13:39SPEAKER_01: The medical fuels calls those tight junctions.
- 13:42SPEAKER_01: That solid, unbroken stone wall is what keeps the invading gut bacteria safely outside in the digestive tract, away from the inner keep of the body.
- 13:50SPEAKER_00: But in ulcerative colitis, the mortar cracks.
- 13:53SPEAKER_01: The tight junctions break down, the wall becomes porous.
- 13:56SPEAKER_00: And once that wall is breached, the bacteria naturally living in your gut pour through the cracks.
- 14:01SPEAKER_00: The immune guard dogs inside the castle wall detect the breach and go absolutely crazy.
- 14:06SPEAKER_01: Which creates a massive wave of inflammation, and that inflammation just damages the stone wall even more.
- 14:10SPEAKER_01: It's a devastating feedback loop.
- 14:12SPEAKER_01: It is.
- 14:13SPEAKER_01: But the MSCs arrive and repair those tight junctions.
- 14:17SPEAKER_01: They lay down fresh mortar, sealing the wall back up.
- 14:20SPEAKER_00: And they take it one step further by increasing the production of mucin.
- 14:23SPEAKER_00: Think of mucin as the thick, protective moat situated just outside that newly repaired castle wall.
- 14:31SPEAKER_01: So you rebuild the impenetrable wall and you refill the protective moat.
- 14:34SPEAKER_01: By physically restoring that barrier, you have completely stopped the bacteria from crossing over.
- 14:40SPEAKER_00: Exactly.
- 14:40SPEAKER_00: You remove the very trigger that starts the immune attacks in the first place.
- 14:44SPEAKER_01: That is so cool.
- 14:45SPEAKER_00: And the clinical data backs this structural restoration up completely.
- 14:49SPEAKER_00: In laboratory models where researchers deliberately destroy the gut barrier, introducing MSE extracts directly and actively restores that barrier integrity.
- 14:59SPEAKER_01: So it isn't just a happy side effect of having less inflammation.
- 15:03SPEAKER_00: No.
- 15:03SPEAKER_00: The MSCs send a direct active signal, forcing the tissue to regenerate.
- 15:07SPEAKER_01: That structural reality on a cellular level is incredible.
- 15:11SPEAKER_01: But you know, the ultimate test is what happens when this biological mechanism is applied to actual human beings suffering from this disease.
- 15:18SPEAKER_00: Yeah.
- 15:18SPEAKER_01: Rebuilding that physical barrier has to translate directly into clinical outcomes.
- 15:23SPEAKER_01: And the data presented in these sources is just incredibly compelling.
- 15:27SPEAKER_00: It really is.
- 15:28SPEAKER_00: Looking at the data from phase I and phase two clinical trials for MSC therapy and ulcerative colitis, we are saying response rates typically ranging between 60 to 75 percent.
- 15:38SPEAKER_01: Let's pause on that.
- 15:39SPEAKER_01: 60 to 75 percent is a massive response rate, especially when you consider that clinical trials usually enroll patients who have already failed multiple rounds of standard heavy-duty treatments.
- 15:51SPEAKER_00: Exactly.
- 15:51SPEAKER_00: These are often the toughest cases.
- 15:53SPEAKER_01: And the researchers aren't just asking patients if they feel better subjectively, right?
- 15:57SPEAKER_00: No, they are tracking meaningful documented reductions in standardized disease activity scores, like the Mayo score.
- 16:04SPEAKER_00: Okay.
- 16:05SPEAKER_00: And more importantly, they are seeing significant objective drops in blood markers, specifically CRP and ESR.
- 16:12SPEAKER_01: Let's decode those.
- 16:13SPEAKER_01: Think of CRPC reactive protein and ESR is systemic smoke alarms circulating in your blood.
- 16:19SPEAKER_00: Great way to put it.
- 16:19SPEAKER_01: If those numbers are elevated, your whole biological house is essentially on fire, even if you can't point to the flames.
- 16:25SPEAKER_01: Watching those specific numbers drop means the systemic fire is actually going out.
- 16:29SPEAKER_00: And the most crucial element of these trials is the duration of the relief.
- 16:33SPEAKER_00: Follow-up studies are demonstrating that patients who respond well are maintaining these clinical improvements at the 12-month and 24-month marks.
- 16:42SPEAKER_01: So this isn't a temporary two-week band-aid.
- 16:44SPEAKER_00: Not at all.
- 16:45SPEAKER_01: It makes perfect biological sense when you step back.
- 16:48SPEAKER_01: We established that MSEs massively expand the regulatory T cells, the brakes, and they physically rebuild the tight junctions of the gut barrier.
- 16:56SPEAKER_00: The compounding inevitable result of those two mechanisms working in tandem is fewer flares over time.
- 17:03SPEAKER_01: You have a fortified wall keeping the bacterial triggers out, and a deeply calmed immune system that no longer overreacts.
- 17:09SPEAKER_00: But we also have to weigh this efficacy against the safety profile.
- 17:13SPEAKER_01: Absolutely.
- 17:14SPEAKER_00: Because for a patient, fear of side effects dictates so much of their decision making.
- 17:19SPEAKER_00: We detailed the severe risks of long-term biologics or steroids earlier: the osteoporosis, organ toxicity, the constant fear of catching a severe enforction.
- 17:29SPEAKER_01: Right.
- 17:30SPEAKER_00: So, how does the safety of MSc therapy compare?
- 17:33SPEAKER_01: It's almost shockingly mild by comparison.
- 17:35SPEAKER_01: The safety profile of MSCs emerges as one of its most distinct advantages.
- 17:40SPEAKER_01: The most commonly reported side effects in the clinical trials are remarkably temporary.
- 17:45SPEAKER_00: What are we talking about here?
- 17:46SPEAKER_01: Patients typically experience things like a low-grade fever or mild discomfort from the IV infusion itself, which generally resolves within a few hours.
- 17:54SPEAKER_00: Okay.
- 17:54SPEAKER_01: There might be some minor temporary changes in bowel habits during the first few weeks as the gut architecture adjusts and begins healing.
- 18:01SPEAKER_00: That makes sense.
- 18:02SPEAKER_01: But there is zero bone density loss.
- 18:04SPEAKER_01: There is no organ toxicity.
- 18:06SPEAKER_01: The published clinical studies report no systemic increase in infection risk and no cases of malignancy linked to the WJMSC treatment.
- 18:14SPEAKER_01: For a patient who has spent years suffering through the terrifying side effects of heavy immunosuppressants, looking at this safety profile has to feel like a massive weight lifted.
- 18:24SPEAKER_00: Aaron Powell It leads to an obvious question though.
- 18:27SPEAKER_00: If this therapy works so effectively, if it actively heals the mucosal barrier, drops the flare rates, and boasts this remarkably mild safety profile, why isn't it the very first thing every single UC patient is handed the moment they get diagnosed?
- 18:43SPEAKER_01: Aaron Powell It's a great question.
- 18:44SPEAKER_01: And it brings us to the clinical philosophy of seronacell.
- 18:47SPEAKER_01: They address this directly in the documents.
- 18:50SPEAKER_01: MSC therapy is not a first-line treatment.
- 18:52SPEAKER_00: Right.
- 18:53SPEAKER_01: And honestly, any reputable regenerative medicine clinic will be the very first to sit you down and tell you that.
- 18:57SPEAKER_00: Yeah, if you are a patient who just got diagnosed with mild UC and a cheap, basic daily pill keeps you in stable, comfortable remission, you stay on that medication.
- 19:06SPEAKER_01: Exactly.
- 19:07SPEAKER_00: Cirrona Cell clearly positions MSc therapy as an advanced adjunct option.
- 19:12SPEAKER_00: It is primarily designed for patients dealing with moderate to severe disease who have hit a wall.
- 19:17SPEAKER_01: Patients who have failed at least one standard treatment option or whose bodies simply cannot tolerate the grueling side effects of their current drug regimen.
- 19:26SPEAKER_00: Let's highlight that word.
- 19:27SPEAKER_00: Adjunct.
- 19:28SPEAKER_00: It works alongside standard care.
- 19:31SPEAKER_01: That's a crucial point.
- 19:32SPEAKER_00: Many patients who come in for this therapy are still taking their background medications, whether those are biologics or steroids, right up to the day of the infusion.
- 19:40SPEAKER_01: Aaron Powell You don't just stop everything cold turkey.
- 19:43SPEAKER_00: No, the medical goal is not to dramatically rip you off all your medications on day one.
- 19:48SPEAKER_00: That would be incredibly dangerous.
- 19:50SPEAKER_00: Right.
- 19:51SPEAKER_00: The objective is to use the MSCs to reduce the disease activity and physically heal the mucosa to such a degree that eventually, working closely under your primary gastroenterologist's supervision, those heavy medication doses can be safely and slowly dialed back.
- 20:07SPEAKER_01: And that step-down approach speaks volumes about Cyrona cell's entire ethos.
- 20:12SPEAKER_01: The materials strongly emphasize their commitment to transparent, honest medical advice.
- 20:17SPEAKER_00: They aren't just selling you something.
- 20:19SPEAKER_01: Not at all.
- 20:20SPEAKER_01: Their medical team doesn't just book an infusion, they review your comprehensive medical history, your recent colonoscopy results, your current medication list.
- 20:29SPEAKER_00: Very thorough.
- 20:30SPEAKER_01: Yeah.
- 20:30SPEAKER_01: And if they evaluate your case and see that you have far too much permanent physical scar tissue damage on the colon, or conversely, if your disease is just too mild to warrant the procedure, they will honestly inform you that you won't benefit from their program.
- 20:45SPEAKER_00: Which is exactly how advanced regenerative medicine must be practiced to maintain integrity.
- 20:50SPEAKER_00: Exactly.
- 20:51SPEAKER_00: They actively coordinate care with the patient's existing specialists.
- 20:55SPEAKER_00: Their entire priority structure is based on building long-term clinical trust and providing highly structured, medically supervised care rather than acting like a clinic selling a one-time miracle cure.
- 21:06SPEAKER_01: No quick fix promises.
- 21:11SPEAKER_00: It's refreshing.
- 21:12SPEAKER_01: It really is.
- 21:12SPEAKER_01: So let's take a moment to recap the journey we've mapped out today.
- 21:15SPEAKER_01: We started by exploring how standard UC care, while initially vital, often hits a ceiling.
- 21:21SPEAKER_01: It acts like baling water from a boat without fixing the leak, forcing the adaptable immune system to find dangerous workarounds.
- 21:28SPEAKER_00: And we then broke down how ethically sourced, highly regulated MSCs act as a peracrine reset button.
- 21:34SPEAKER_00: They track down the inflammation, silence the biochemical attack alarms, and simultaneously boost the regulatory breaks of the immune system.
- 21:42SPEAKER_01: Which finally affords the body the space it needs to physically rebuild that mucosal barrier, restoring the tight junctions of the castle wall, and refilling the mucin mode.
- 21:51SPEAKER_00: And this structural repair leads to the incredibly promising clinical outcomes we see in the data.
- 21:56SPEAKER_00: Fewer flares, lasting remission, and a safety profile that offers genuine hope.
- 22:02SPEAKER_01: All of this managed through the structured, honest adjunct approach of clinics like Cyrusella Malaysia.
- 22:07SPEAKER_00: It represents a profound fundamental shift in how medicine approaches chronic inflammatory disease.
- 22:12SPEAKER_00: We are moving from mere suppression to active regeneration.
- 22:16SPEAKER_01: We really are.
- 22:17SPEAKER_01: Now, before we sign off, I want to leave you with one final, incredibly fascinating ripple effect mentioned deep in the research sources.
- 22:24SPEAKER_01: We didn't have time to fully unpack it today, but it is something profound to ponder.
- 22:29SPEAKER_00: Oh, I know what you're gonna say.
- 22:30SPEAKER_01: It involves the gut microbiome.
- 22:32SPEAKER_01: We know that MSCs calm systemic inflammation and rebuild that protective mucin layer.
- 22:38SPEAKER_01: But in doing so, they actually change the physical environment of the colon, making it significantly friendlier for beneficial bacteria to survive and thrive.
- 22:47SPEAKER_00: Yeah, some clinical studies are observing actual measurable shifts in the microbiome balance after MSC treatment, where good bacterial strains become dominant again.
- 22:56SPEAKER_01: It creates a brilliant biological feedback loop.
- 22:58SPEAKER_01: Yeah, really leaves you wondering: you know, could healing the physical structural architecture of our gut fundamentally alter the microscopic ecosystem living inside us?
- 23:08SPEAKER_00: That's a huge question.
- 23:09SPEAKER_01: Could repairing the walls of the castle actually invite better, stronger allies to take up residence inside, creating a permanent living shield against future disease?
- 23:19SPEAKER_00: It's a beautiful, staggering thought about the interconnectedness of the human body.
- 23:25SPEAKER_01: It really is.
- 23:26SPEAKER_01: Thank you so much for joining us on this deep dive.
- 23:28SPEAKER_01: We'll catch you next time.